IXICO has been selected for a contract to provide MRI and DAT-SPECT imaging services by an unidentified European biopharmaceutical company for a Phase 2 clinical trial in Parkinson’s disease.
The contract represents the second study award IXICO has received from the client over the last 12 months, with the trial expected to progress over four and a half years.
IXICO is reportedly set to provide radiology and quantitative analysis services to support patient selection, safety and efficacy analysis.
The contract will build on the pharmaceutical group’s portfolio of proprietary imaging data management and analysis technologies for the investigation of neurological disorders across the drug development lifecycle, from phase one to commercialisation.
“We are delighted to be awarded this contract to support the development of this promising investigational drug in PD,” said IXICO CEO Giulio Cerroni.
“Our success in being awarded a second study with this client, demonstrates the momentum we are building in expanding into a broader range of neurodegenerative therapeutic indications.”
“Our mission is to support our current and prospective clients in their efforts to bring potential treatments to patients suffering from neurological disorders, and this contract is an example of the confidence that increasing numbers of companies are placing in IXICO as their trusted neuroimaging partner for their important CNS studies.”
